Active Clinical Trials

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

By April 24, 2017No Comments


Malignant Peritoneal Mesothelioma

Estimated Enrollment: 35

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 12-0032|NCI-2012-00332

Study First Received: May 3, 2012

Last Updated: June 24, 2016

Estimated Primary Completion Date: June 2017


Primary Outcome Measures:

Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|PFS|OS|Toxicity in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0|Disease control rate – SD + PR + CR|Percentage of patients who have activating EGFR mutations among all screened patients

Sponsors and Collaborators:

University of Chicago|National Cancer Institute (NCI)

Website Link:

Leave a Reply

Call Now ButtonCall Now